@FierceMedDev: Volcano green-lights a $200M share buyback under M&A pressure. News | Follow @FierceMedDev
@MarkHFierce: Inogen joins a select group of med device companies that have filed IPO plans this year. Article | Follow @MarkHFierce
@MichaelGFierce: Check out FierceBiotech's Top Women in Biotech 2013. More | Follow @MichaelGFierce
@GalenMoore: Xlumena brings in hedge fund Third Point for a $25M Series C aimed at FDA approval. Story | Follow @GalenMoore
> Blaze Bioscience snagged $9 million in Series B financing for its Tumor Paint technology, a combination optide and fluorescent dye that helps illuminate cancer cells during surgery. Item
> AcelRx is aiming for a Sept. 2014 approval date for its handheld, automated, pre-programmed pain drug delivery system. Story
> A group with Burrill & Company, a San Francisco VC, has split off into a new venture firm called Biomark Capital. Story
> Medgenics' board chairman has purchased more than 20,000 shares of the company's common stock. Item
> German researchers took a step toward developing better hearing aids by building a computer model of acoustic coding in the inner ear and the neuronal information processing by the brain stem. Item
Biotech News
@FierceBiotech: Xencor Prices Initial Public Offering. Release | Follow @FierceBiotech
@JohnCFierce: Sanofi is touting U300 PhIII diabetes data. Important program for the co. Release (PDF) | Follow @JohnCFierce
@DamianFierce: Kinda disappointed Celgene couldn't get more arcane clauses into this OncoMed deal. Story | Follow @DamianFierce
@EmilyMFierce: Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More | Follow @EmilyMFierce
> Sanofi touts promising PhIII data on next-gen diabetes therapy as rivals circle. Story
> Angel investors ante up $9M to fuel Blaze's early-stage program for 'tumor paint'. Report
> Novo CEO claims 'strong' pipeline effort will boost sales. Item
Pharma News
@FiercePharma: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole. Release | Follow @FiercePharma
@EricPFierce: Takeda tries on outsider for CEO. Forest tees up cuts. GSK's Witty heads to China. Read it in FiercePharma. More | Follow @EricPFierce
@CarlyHFierce: ICYMI in FierceBiomarkers: Protein C4d linked to higher mortality rates in lung cancer patients. Story | Follow @CarlyHFierce
> Pfizer keeps piling onto consumer health business. Story
> Sources: Bayer, others kicking tires on Novartis animal health business. Article
> Novo expects to keep pumping out growth in insulin market. More
Pharma Manufacturing News
> Irish plant shutdown move puts another Merck site on the block. More
> Wockhardt braces for lost sales after FDA bans its main plant. Story
> Gland Pharma targets U.S. injectables sector after securing $200M. Article
> India drops plans to limit foreign ownership of production capacity. News
> FDA outlines plans for new compounding pharmacy powers. Report
> Hedge fund ups the ante in game of chicken with McKesson. Item
Biotech Research News
> NIH announces $100M for new HIV research initiative. Story
> Key hep C protein revealed, paving the way for new vaccines. News
> Novartis team IDs new malaria target. Article
> NIH publishes first Alzheimer's genomics data for researchers. Report
> Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More
> Study: Standardization needed for drug screening studies. Item